|
Gastrointestinal nonspecific inflammation and dysfunctional conditions
|
114
|
4.27 (3.48,5.23)*
|
948
|
3.23 (3.00,3.48)*
|
86
|
2.53 (2.02,3.17)*
|
37
|
2.50 (1.78,3.52)*
|
1180
|
3.39 (3.17,3.63)*
|
|
Hypersensitivity
|
113
|
8.04 (6.55,9.87)*
|
732
|
4.91 (4.51,5.35)*
|
68
|
3.68 (2.86,4.73)*
|
22
|
2.66 (1.73,4.10)*
|
932
|
5.47 (5.05,5.91)*
|
|
Acute pancreatitis
|
79
|
11.27 (8.87,14.33)*
|
738
|
14.99 (13.54,16.58)*
|
42
|
4.62 (3.37,6.33)*
|
7
|
1.69 (0.80,3.58)
|
862
|
16.32 (14.76,18.04)*
|
|
Haemodynamic oedema, effusions and fluid overload
|
40
|
2.26 (1.64,3.11)*
|
329
|
1.64 (1.46,1.84)*
|
23
|
1.06 (0.70,1.61)
|
21
|
2.32 (1.49,3.61)*
|
411
|
1.68 (1.52,1.87)*
|
|
Malignancies
|
21
|
1.97 (1.27,3.05)*
|
346
|
3.22 (2.86,3.62)*
|
34
|
2.76 (1.95,3.90)*
|
9
|
1.64 (0.85,3.19)
|
405
|
3.12 (2.79,3.48)*
|
|
Noninfectious diarrhoea
|
44
|
4.28 (3.15,5.83)*
|
250
|
2.15 (1.88,2.46)*
|
28
|
2.22 (1.52,3.25)*
|
20
|
3.75 (2.38,5.91)*
|
341
|
2.48 (2.20,2.79)*
|
|
Angioedema
|
52
|
10.82 (8.10,14.46)*
|
254
|
5.21 (4.52,6.01)*
|
30
|
4.96 (3.43,7.19)*
|
3
|
1.09 (0.35,3.40)
|
337
|
6.20 (5.44,7.07)*
|
|
Embolic and thrombotic events
|
10
|
0.05 (0.03,0.09)
|
180
|
0.07 (0.06,0.09)
|
30
|
0.13 (0.09,0.19)
|
19
|
0.20 (0.12,0.31)
|
239
|
0.08 (0.07,0.09)
|
|
Hepatic disorders
|
15
|
3.53 (2.11,5.92)*
|
148
|
3.40 (2.85,4.07)*
|
8
|
1.56 (0.78,3.15)
|
10
|
4.63 (2.46,8.72)*
|
179
|
3.45 (2.92,4.08)*
|
|
Cardiac failure
|
11
|
0.11 (0.06,0.21)
|
122
|
0.10 (0.09,0.12)
|
23
|
0.20 (0.13,0.31)
|
12
|
0.25 (0.14,0.44)
|
167
|
0.11 (0.10,0.13)
|
|
Hypertension
|
15
|
1.21 (0.73,2.02)
|
118
|
0.81 (0.68,0.98)
|
6
|
0.40 (0.18,0.90)
|
27
|
4.57 (3.08,6.78)*
|
166
|
0.94 (0.80,1.10)
|
|
Chronic kidney disease
|
7
|
0.67 (0.32,1.41)
|
137
|
1.16 (0.98,1.39)
|
12
|
0.98 (0.55,1.74)
|
7
|
1.33 (0.63,2.82)
|
162
|
1.12 (0.95,1.31)
|
|
Arthritis
|
6
|
1.93 (0.86,4.34)
|
79
|
2.39 (1.88,3.03)*
|
10
|
2.76 (1.47,5.17)*
|
3
|
1.89 (0.60,5.90)
|
97
|
2.43 (1.96,3.03)*
|
|
Gastrointestinal perforation, ulceration, haemorrhage or obstruction
|
6
|
1.60 (0.71,3.59)
|
66
|
1.58 (1.23,2.04)*
|
11
|
2.52 (1.38,4.58)*
|
7
|
3.72 (1.75,7.89)*
|
90
|
1.79 (1.44,2.24)*
|
|
Dyslipidaemia
|
8
|
1.38 (0.68,2.78)
|
70
|
1.05 (0.82,1.34)
|
2
|
0.29 (0.07,1.15)
|
3
|
1.01 (0.32,3.15)
|
82
|
1.00 (0.79,1.25)
|
|
Severe cutaneous adverse reactions
|
6
|
4.84 (2.14,10.91)*
|
62
|
5.34 (4.01,7.13)*
|
8
|
5.51 (2.72,11.19)*
|
4
|
6.30 (2.33,17.01)*
|
80
|
6.12 (4.69,8.00)*
|
|
Depression and suicide/self-injury
|
9
|
1.74 (0.90,3.37)
|
60
|
1.00 (0.77,1.30)
|
6
|
0.97 (0.44,2.18)
|
5
|
1.89 (0.78,4.59)
|
80
|
1.09 (0.87,1.37)
|
|
Retinal disorders
|
4
|
1.29 (0.48,3.45)
|
34
|
0.95 (0.67,1.34)
|
7
|
1.92 (0.91,4.07)
|
3
|
1.90 (0.61,5.93)
|
46
|
1.05 (0.78,1.42)
|
|
Taste and smell disorders
|
0
|
–
|
37
|
2.82 (1.99,4.00)*
|
2
|
1.34 (0.33,5.40)
|
4
|
6.32 (2.34,17.08)*
|
43
|
2.70 (1.94,3.76)*
|
|
Anaphylactic reaction
|
11
|
7.23 (3.94,13.26)*
|
25
|
1.40 (0.93,2.11)
|
3
|
1.61 (0.51,5.02)
|
3
|
3.74 (1.20,11.73)*
|
39
|
2.01 (1.45,2.78)*
|
